PMA, or Premarket Approval, is the most rigorous regulatory pathway the FDA uses to evaluate medical devices before they can be sold in the United States. It applies specifically to Class III medical devices, the highest-risk category, which includes things like heart valves, implantable pacemakers, and breast implants. Unlike the simpler 510(k) clearance process used for lower-risk devices, PMA requires manufacturers to submit clinical trial data proving their device is both safe and effective.
Which Devices Need PMA
The FDA classifies all medical devices into three categories based on risk. Class I covers low-risk items like bandages and tongue depressors. Class II includes moderate-risk devices like powered wheelchairs and pregnancy tests. Class III is reserved for devices that support or sustain human life, play a substantial role in preventing serious health problems, or present a potentially unreasonable risk of illness or injury.
For Class I and II devices, the FDA relies on general controls (like labeling requirements) and special controls (like performance standards) to keep patients safe. For Class III devices, the agency has determined those controls aren’t enough on their own. That’s where PMA comes in: it requires the manufacturer to submit a full application backed by scientific evidence, including data from clinical trials in humans, before the device can reach the market.
How PMA Differs From 510(k) Clearance
The distinction between PMA and 510(k) trips up a lot of people, partly because the terms “approval” and “clearance” sound interchangeable. They’re not. A 510(k) submission asks the FDA a narrow question: is this new device substantially equivalent to one that’s already legally on the market? If the device has the same intended use and similar technology as a predicate device, and doesn’t raise new safety concerns, the FDA clears it. No clinical trials are typically required.
PMA asks a fundamentally different question: does valid scientific evidence demonstrate that this device is safe and effective? There’s no predicate device to lean on. The manufacturer must generate original data, usually through controlled clinical studies, and submit it for deep review. If a device submitted through the 510(k) pathway is found not substantially equivalent to any existing device, the manufacturer’s options include filing a PMA application instead.
What the Application Includes
A PMA application is enormous. It spans multiple volumes covering the device description and intended use, nonclinical laboratory studies (animal testing, biocompatibility, stress and fatigue engineering tests, shelf life data), clinical study results with individual case report forms, manufacturing methods, and proposed labeling. The applicant must present a conclusion demonstrating that all this evidence provides “reasonable assurance” the device is safe and effective for its intended use, including a discussion of risks versus benefits.
The clinical evidence is the centerpiece. The FDA’s standard for valid scientific evidence includes well-controlled investigations, partially controlled studies, objective trials without matched controls, well-documented case histories, and reports of significant human experience with a marketed device. In practice, the agency expects the effectiveness data to come principally from well-controlled investigations, meaning randomized clinical trials with appropriate comparison groups.
The Four-Step Review Process
Once a PMA lands at the FDA, it moves through four distinct phases.
Acceptance and filing review. FDA staff conduct an administrative and limited scientific review to confirm the application is complete. Within 45 days of receiving the submission, the agency notifies the applicant whether it has been filed. Filing doesn’t mean the device is approved; it means the application is complete enough to warrant a full review. The 180-day review clock starts on the filing date.
Substantive review. This is the deep dive. FDA scientists, statisticians, and engineers evaluate every component: nonclinical study data, clinical trial results, manufacturing processes, and proposed labeling. The agency also conducts a Quality System inspection at the manufacturing facility and may audit the clinical study sites to verify data integrity. If the review team identifies gaps, they send the applicant deficiency letters requesting additional information.
Advisory committee review. For some PMAs, the FDA convenes an independent panel of outside experts to review the evidence and make a recommendation. This step isn’t required for every application, but when it happens, the FDA targets issuing its decision within 60 days of the committee’s recommendation.
Final decision. The FDA issues an approval order (along with a Summary of Safety and Effectiveness Data and final labeling) or denies the application. The agency can deny a PMA if the evidence doesn’t demonstrate reasonable assurance of safety and effectiveness, or if the application fails to meet other statutory requirements.
How Long It Takes
The statutory review period is 180 FDA days, but “FDA days” excludes time the agency is waiting on the applicant to respond to deficiency letters. In real calendar time, the process takes considerably longer. The current performance goal, set under the Medical Device User Fee Amendments, targets an average total time to decision of 285 calendar days for original PMAs submitted in fiscal years 2025 through 2027. For applications that require advisory committee input, the FDA aims to issue a decision within 320 FDA days for 90% of submissions.
These timelines cover only the formal review. Companies typically spend years before that point designing studies, running clinical trials, and compiling their application. From the start of clinical testing to PMA approval, the total development timeline for a Class III device often stretches well beyond five years.
Three Ways to Submit a PMA
The traditional method is straightforward: compile everything and submit the entire application at once. But the FDA also offers two alternative approaches designed to make the process more collaborative.
A Modular PMA breaks the application into discrete sections, or modules. The manufacturer submits each module as it’s completed, starting with a “shell” document that outlines the plan. FDA reviewers evaluate each module as it arrives and provide feedback along the way. By the time the final module is submitted, much of the review work is already done, which can shorten the time between final submission and decision.
A Product Development Protocol (PDP) merges the clinical evaluation and the regulatory review into a single process from the very beginning. The manufacturer and FDA agree early on about exactly what evidence will be needed to demonstrate safety and effectiveness, with reporting milestones built in throughout development. When the FDA declares a PDP complete, it functions as an approved PMA.
What It Costs
PMA applications carry substantial user fees paid to the FDA. For fiscal year 2026 (October 2025 through September 2026), the standard fee for an original PMA is $579,272. Companies that qualify as small businesses pay a reduced fee of $144,818. These fees cover the FDA’s review costs and don’t include the far larger expenses of conducting the clinical trials and preparing the application itself, which can run into tens of millions of dollars depending on the device.
What Happens After Approval
PMA approval isn’t the end of the regulatory relationship. The FDA can impose post-approval requirements as a condition of the approval order, and continued approval depends on meeting them.
Every PMA holder must submit annual reports at one-year intervals from the date of approval. These reports cover any changes made to the device, summaries of new clinical or nonclinical data, and relevant scientific literature. Any significant change to the device’s design, manufacturing, or labeling requires a PMA supplement, which is its own submission reviewed by the FDA before the change can be implemented.
The FDA can also order post-market surveillance studies, either at the time of approval or afterward, if the device meets certain criteria: its failure could cause serious health consequences, it’s implanted for more than a year, it has significant pediatric use, or it’s a life-sustaining device used outside a healthcare facility. These studies track real-world performance and can involve thousands of patients over several years. The agency may also restrict how a device is sold, distributed, or used, and require manufacturers to maintain tracking systems that identify every patient who receives an implanted device.